Point-of-care blood gas analyzers remain vulnerable to pre-analytical interferences. The authors set out to evaluate the GEM® Premier™ 7000's integrated hemolysis detection, which uses multi-wavelength co-oximetry to estimate free hemoglobin directly in whole blood. The report examined two complementary approaches: assessment of routine patient samples with experimentally induced hemolysis, and controlled hemoglobin overload experiments using distinct hemoglobin variants. The study team reported results intended to clarify whether variant hemoglobins — including HbS and HbF — affect detection performance compared with adult hemoglobin (HbA0).
Fifty patient arterial blood samples undergoing routine blood gas and biochemical testing were analyzed on the GEM® Premier™ 7000 and compared to Atellica Solution analyzer results. Experimental hemolysis was induced to evaluate how the onboard detection changed with increasing free hemoglobin. In a separate set of experiments, samples from 10 healthy volunteers were used for hemoglobin overload tests: investigators added HbA0, HbS, or HbF to probe robustness against variant hemoglobins. The abstract did not include step-by-step reagent volumes, the precise method of inducing hemolysis, or detailed timing parameters; the source did not report those methodological specifics.
The induced hemolysis experiments produced measurable analytic shifts. Data indicated that experimental hemolysis increased the hemolysis index and produced large rises in measured potassium on the GEM® Premier™ 7000. Median hemolysis index values rose from 1 to 6, while median potassium concentrations increased from 3.6 to 9.8 mmol/L. The study team reported this change reached statistical significance (p<0.001). These paired findings demonstrate the platform's susceptibility, like other point-of-care analyzers, to pre-analytical red cell rupture affecting electrolyte results and hemolysis indices. Investigators noted the onboard system registered the trend in free hemoglobin as hemolysis intensified, permitting correlation between instrument hemolysis signal and clinically relevant potassium elevations.
Investigators evaluated whether hemoglobin variant composition altered the device's ability to detect free hemoglobin. During overload experiments with HbA0, HbS, and HbF, the GEM® Premier™ 7000 consistently detected increasing concentrations of free hemoglobin across all three types. The authors reported that the multi-wavelength co-oximetry approach provided accurate detection throughout the overload series. The abstract did not quantify detection limits for each variant, nor did it provide concentration-by-concentration performance matrices; those specific analytic thresholds were not included in the source text. Nevertheless, the experimental result set indicates that variant hemoglobins did not prevent the onboard system from identifying rising free hemoglobin levels under the tested conditions.
Clinicians rely on point-of-care blood gas results in time-sensitive settings. False elevations in potassium caused by hemolysis can prompt inappropriate treatment if unrecognized. The authors argued that integrating an onboard hemolysis detection mechanism enables more reliable interpretation of whole blood gas results by directly estimating free hemoglobin. The GEM® Premier™ 7000's detection, working across HbA, HbS, and HbF, suggests applicability in populations with hemoglobin variants — for example, patients with sickle cell trait/disease or neonates with elevated fetal hemoglobin — although the report did not describe clinical outcome data or decision thresholds for therapy changes.
The abstract documents core findings but leaves several operational and analytic questions unanswered. The source did not report exact hemoglobin concentration thresholds for hemolysis alerts, limits of detection for each hemoglobin variant, or full methodological details for the overload and hemolysis induction protocols. The sample size for overload experiments was ten healthy volunteers, and the patient cohort totaled fifty samples; the abstract did not present subgroup breakdowns, confidence intervals, or extended statistical tables. Investigators did report statistically significant shifts in median hemolysis index and potassium with induced hemolysis, yet readers will need the full text to assess reproducibility, clinical decision thresholds, and potential interference at borderline free hemoglobin concentrations.
The study team concluded that the integrated hemolysis detection reliably detected clinically significant hemolysis in whole blood samples, supporting more reliable point-of-care blood gas testing. Access to the full article will be required to review detailed protocols, analytic limits, and any additional comparative performance data versus laboratory analyzers.